Current developments in the combination therapy of relapsed/refractory multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma therapy has advanced significantly with novel agents and combinations.
• Relapsed or refractory disease still presents challenges, necessitating new treatment strategies.
• Despite progress, multiple myeloma remains an incurable malignancy.

Purpose of the Study:

• To review recent data on managing relapsed/refractory multiple myeloma.
• To discuss the rationale behind selecting agents, regimens, and combinations.
• To highlight promising emerging therapeutic approaches.

Main Methods:

• Review of literature and trial abstracts published or presented up to 2019.
• Focus on data related to relapsed/refractory multiple myeloma management.
• Inclusion of studies on novel agents, combinations, and emerging therapies.

Main Results:

• Significant improvements in patient outcomes have been achieved with non-cross-resistant drugs in multidrug regimens.
• Emerging molecular and cellular biology insights are driving new therapeutic development.
• Antibody-drug conjugates, T-cell-directed therapies, and novel small molecules show promise.

Conclusions:

• Therapeutic strategies for multiple myeloma are continuously evolving.
• Targeting specific biology, such as B cell maturation antigen, with platforms like antibody-drug conjugates is a key development.
• Upcoming approvals and optimized sequencing of therapies are expected to improve patient outcomes.